Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis

PeerJ

Volumn 2015, Issue 5, 2015, Pages

  Meng, Jia ^a   Zhang, Dapeng ^b   Pan, Nanan ^a   Sun, Ning ^a   Wang, Qiujun ^a   Fan, Jingxue ^a   Zhou, Ping ^a   Zhu, Wenliang ^a   Jiang, Lihong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; MicroRNA; miR 194; Postmenopausal osteoporosis

Indexed keywords

MICRORNA;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM; SIGNAL TRANSDUCTION; UPREGULATION; VALIDATION PROCESS;

EID: 84930635300     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.971     Document Type: Article

References (40)

1. Bland JM, Altman DG. 1995. Multiple significance tests: the Bonferroni method. British Medical Journal 310(6973):170 DOI 10.1136/bmj.310.6973.170.
2. Bushati N, Cohen SM. 2007. microRNA functions. Annual Review of Cell and Developmental Biology 23:175-205 DOI 10.1146/annurev.cellbio.23.090506.123406.
3. Cao Z, Moore BT, Wang Y, Peng XH, Lappe JM, Recker RR, Xiao P. 2014. MiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis. PLoS ONE 9(5):e97098 DOI 10.1371/journal.pone.0097098.
4. Chan A, Van Bezooijen RL, Löwik CW. 2007. A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Current Opinion in Investigational Drugs 8(4):293-298.
5. Feng Z, Liu C, Guan X, Mor V. 2012. China's rapidly aging population creates policy challenges in shaping a viable long-term care system. Health Affairs 31(12):2764-2773 DOI 10.1377/hlthaff.2012.0535.
6. Garnero P. 2014. New developments in biological markers of bone metabolism in osteoporosis. Bone 66:46-55 DOI 10.1016/j.bone.2014.05.016.
7. Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J. 2010. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. British Journal of Cancer 103(5):693-700 DOI 10.1038/sj.bjc.6605833.
8. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, Jian TY, Lin FM, Chang TH, Weng SL, Liao KW, Liao IE, Liu CC, Huang HD. 2014. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Research 42(D1):D78-D85 DOI 10.1093/nar/gkt1266.
9. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4(1):44-57 DOI 10.1038/nprot.2008.211.
10. Jeong BC, Kang IH, Hwang YC, Kim SH, Koh JT. 2014. MicroRNA-194 reciprocally stimulates osteogenesis and inhibits adipogenesis via regulating COUP-TFII expression. Cell Death and Disease 5:e1532 DOI 10.1038/cddis.2014.485.
11. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M. 2006. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Research 34(Database issue):D354-D357 DOI 10.1093/nar/gkj102.
12. Kanis JA. 2002. Diagnosis of osteoporosis and assessment of fracture risk. The Lancet 359(9321):1929-1936 DOI 10.1016/S0140-6736(02)08761-5.
13. Kanterewicz E, Puigoriol E, Garcí{dotless}a-Barrionuevo J, del Rio L, Casellas M, Peris P, Frodos Research Group. 2014. Prevalence of vertebral fractures and minor vertebral deformities evaluated by DXA-assisted vertebral fracture assessment (VFA) in a population-based study of postmenopausal women: the FRODOS study. Osteoporosis International 25(5):1455-1464 DOI 10.1007/s00198-014-2628-2.
14. Kowarsch A, Preusse M, Marr C, Theis FJ. 2011. miTALOS: analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs. RNA 17(5):809-819 DOI 10.1261/rna.2474511.
15. Kozomara A, Griffiths-Jones S. 2014. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Research 42(Database issue):D68-D73 DOI 10.1093/nar/gkt1181.
16. Krishnan V, Bryant HU, Macdougald OA. 2006. Regulation of bone mass by Wnt signaling. The Journal of Clinical Investigation 116(5):1202-1209 DOI 10.1172/JCI28551.
17. Li H, Wang Z, Fu Q, Zhang J. 2014. Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients. Biomarkers 19(7):553-556 DOI 10.3109/1354750X.2014.935957.
18. Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, Luo XH. 2009. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. The Journal of Clinical Investigation 119(12):3666-3677 DOI 10.1172/JCI39832.
19. Lian JB, Stein GS, Van Wijnen AJ, Stein JL, Hassan MQ, Gaur T, Zhang Y. 2012. MicroRNA control of bone formation and homeostasis. Nature Reviews Endocrinology 8(4):212-227 DOI 10.1038/nrendo.2011.234.
20. Manolagas SC, Jilka RL. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. New England Journal of Medicine 332(5):305-311 DOI 10.1056/NEJM199502023320506.
21. Matsuoka K, Park KA, Ito M, Ikeda K, Takeshita S. 2014. Osteoclast-derived complement component 3a stimulates osteoblast differentiation. Journal of Bone and Mineral Research 29(7):1522-1530 DOI 10.1002/jbmr.2187.
22. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 105(30):10513-10518 DOI 10.1073/pnas.0804549105.
23. Naeem H, Küffner R, Csaba G, Zimmer R. 2010. miRSel: automated extraction of associations between microRNAs and genes from the biomedical literature. BMC Bioinformatics 11:135 DOI 10.1186/1471-2105-11-135.
24. Nistala H, Lee-Arteaga S, Siciliano G, Smaldone S, Ramirez F. 2010. Extracellular regulation of transforming growth factor β and bone morphogenetic protein signaling in bone. Annals of the New York Academy of Sciences 1192(1):253-256 DOI 10.1111/j.1749-6632.2009.05350.x.
25. Rachner TD, Khosla S, Hofbauer LC. 9773. Osteoporosis: now and the future. The Lancet 377:1276-1287 DOI 10.1016/S0140-6736(10)62349-5.
26. Raisz LG. 2005. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. The Journal of Clinical Investigation 115(12):3318-3325 DOI 10.1172/JCI27071.
27. Rawadi G, Roman-Roman S. 2005. Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opinion on Therapeutic Targets 9(5):1063-1077 DOI 10.1517/14728222.9.5.1063.
28. Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam FW, Nkenke E. 2014. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncology Reports 31(3):1429-1436 DOI 10.3892/or.2014.2983.
29. Rosen CJ. 2005. Postmenopausal osteoporosis. New England Journal of Medicine 353(6):595-603 DOI 10.1056/NEJMcp043801.
30. Sanders S, Geraci SA. 2013. Osteoporosis in postmenopausal women: considerations in prevention and treatment: (women's health series). Southern Medical Journal 106(12):698-706 DOI 10.1097/SMJ.0b013e3182a0df8b.
31. Sugatani T, Hruska KA. 2007. MicroRNA-223 is a key factor in osteoclast differentiation. Journal of Cellular Biochemistry 101(4):996-999 DOI 10.1002/jcb.21335.
32. Sun GJ, Guo T, Chen Y, Xu B, Guo JH, Zhao JN. 2013. Significant pathways detection in Osteoporosis based on the bibliometric network. European Review for Medical and Pharmacological Sciences 17(1):1-7.
33. Taurino C, Miller WH, McBride MW, McClure JD, Khanin R, Moreno MU, Dymott JA, Delles C, Dominiczak AF. 2010. Gene expression profiling in whole blood of patients with coronary artery disease. Clinical Science 119(8):335-343 DOI 10.1042/CS20100043.
34. Tella SH, Gallagher JC. 2014. Prevention and treatment of postmenopausal osteoporosis. The Journal of Steroid Biochemistry and Molecular Biology 142:155-170 DOI 10.1016/j.jsbmb.2013.09.008.
35. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Marker Standards Working Group. 2011. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International 22(2):391-420 DOI 10.1007/s00198-010-1501-1.
36. Wang Y, Li L, Moore BT, Peng XH, Fang X, Lappe JM, Recker RR, Xiao P. 2012. MiR-133a in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis. PLoS ONE 7(4):e34641 DOI 10.1371/journal.pone.0034641.
37. Xie X, Qin J, Lin SH, Tsai SY, Tsai MJ. 2011. Nuclear receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) modulates mesenchymal cell commitment and differentiation. Proceedings of the National Academy of Sciences of the United States of America 108(36):14843-14848 DOI 10.1073/pnas.1110236108.
38. Xu J, Meng K, Zhang R, Yang H, Liao C, Zhu W, Jiao J. 2014. The use of functional chemical-protein associations to identify multi-pathway renoprotectants. PLoS ONE 9(5):e97906 DOI 10.1371/journal.pone.0097906.
39. Yu W, Wulf A, Liu T, Khoury MJ, Gwinn M. 2008. Gene Prospector: an evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. BMC Bioinformatics 9:528 DOI 10.1186/1471-2105-9-528.
40. Zhao X, Xu D, Li Y, Zhang J, Liu T, Ji Y, Wang J, Zhou G, Xie X. 2014. MicroRNAs regulate bone metabolism. Journal of Bone and Mineral Metabolism 32(3):221-231 DOI 10.1007/s00774-013-0537-7.